Status:
COMPLETED
Serum Clozapine and Cognition
Lead Sponsor:
University of Aarhus
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
This study aim to investigate the relationship between serum levels of clozapine and cognitive performance in patients with ICD-10 Schizophrenia and treated with clozapine monotherapy. The hypothesis ...
Eligibility Criteria
Inclusion
- Treated with clozapine for minimum 6 months.
- Fixed dosage of clozapine last month before inclusion.
Exclusion
- Substance misuse.
- Depression (Calgary Depression score ≥7).
- Somatic disease that interfere with cognitive performance.
- Treatment with benzodiazepines (half-lives \>15 hours not allowed up 14 days prior inclusion and during study. Half-lives \< 15 hours not allowed 3 days prior cognitive testing).
- Electroconvulsive therapy.
- Treatment with other antipsychotics.
- Withdrawal of informed consent.
- Compulsory measures.
- Treatment with anticholinergics except for atropine drops administered sublingually.
- Changes in use of tobacco last month before inclusion.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00951418
Start Date
June 1 2009
End Date
September 1 2013
Last Update
September 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aalborg Psychiatric Hospital
Aalborg, Denmark, 9000